Fidelity International
ACRS icon

Fidelity International’s Aclaris Therapeutics ACRS Stock Holding History

Fidelity International’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,213
Closed -$366K – 843
2018
Q3 		$366K Hold
25,213
– – ﹤0.01% 661
2018
Q2 		$504K Hold
25,213
– – ﹤0.01% 654
2018
Q1 		$442K Buy
+25,213
New +$534K ﹤0.01% 495
2017
Q2 		– Sell
-195,692
Closed -$5.83M – 512
2017
Q1 		$5.83M Sell
195,692
-239,924
-55% -$6.92M 0.02% 394
2016
Q4 		$11.8M Sell
435,616
-190,097
-30% -$4.85M 0.03% 316
2016
Q3 		$16M Sell
625,713
-121,492
-16% -$2.58M 0.05% 282
2016
Q2 		$13.8M Buy
+747,205
New +$14.8M 0.04% 300

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fidelity International's ACRS Position: Q4 2018 in Review

Fidelity International sold out of Aclaris Therapeutics (ACRS) in Q4 2018, closing a stake of 25,213 shares — an estimated $366K sold.

Fidelity International first reported a position in ACRS in Q2 2016 and held it in 7 quarters. The position peaked at $16M in Q3 2016. 99 funds tracked by Wall St. Rank hold ACRS as of Q4 2018.

  • Fidelity International reported no remaining Aclaris Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Fidelity International sold 25,213 Aclaris Therapeutics shares in Q4 2018, an estimated $366K.
  • Fidelity International first reported a position in Aclaris Therapeutics in Q2 2016 and held it in 7 quarters.
  • Fidelity International's Aclaris Therapeutics position peaked at $16M in Q3 2016.
  • 99 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2018.

Based on Fidelity International's 13F filing for Q4 2018, filed 13 Feb 2019.